Starling Oncology Inc (TOI)Healthcare | Medical Care Facilities | Cerritos, United States |
USD
|
Hot Take ↕ | Aug. 22, 2026, 8:05 a.m. UTC
The immediate outlook is neutral-to-slightly-bearish despite a recent pop; the stock is trading below its 50-day average, indicating fading immediate momentum, and the statistical forecast offers only a weak lean upward with low confidence. The long-term picture is severely compromised by deteriorating fundamentals: the company is burning cash with negative free cash flow and operating margins, while the multi-year price trajectory shows a significant decline, suggesting the market has already priced in a lack of sustainable business quality. There is no dividend to provide income or a floor. While analysts are bullish and a major owner recently bought shares, these are insufficient to overcome the structural financial deficits and the clear evidence of a falling asset price over the long term. |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 5.537 |
| Market Cap | 512,912,480 |
| Forward P/E | -32.06 |
| Beta | 0.42 |
| Profit Margins | -7.97% |
| Website | https://theoncologyinstitute.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.5121951 |
| Address1 | 18,000 Studebaker Road |
| Address2 | Suite 800 |
| All Time High | 12.66 |
| All Time Low | 0.1253 |
| Ask | 6.31 |
| Ask Size | 200 |
| Audit Risk | 9 |
| Average Daily Volume10 Day | 1,970,151 |
| Average Volume | 1,991,815 |
| Average Volume10Days | 1,970,151 |
| Beta | 0.422 |
| Bid | 3.68 |
| Bid Size | 200 |
| Board Risk | 5 |
| Book Value | -0.163 |
| City | Cerritos |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Currency | USD |
| Current Price | 5.13 |
| Current Ratio | 1.473 |
| Date Short Interest | 1,784,073,600 |
| Day High | 5.15 |
| Day Low | 4.87 |
| Ebitda | -25,909,000 |
| Ebitda Margins | -0.047470003 |
| Enterprise To Ebitda | -22.677 |
| Enterprise To Revenue | 1.077 |
| Enterprise Value | 587,545,472 |
| Exchange | NCM |
| Exchange Timezone Name | UTC |
| Fifty Day Average | 5.3114 |
| Fifty Two Week High | 7.05 |
| Fifty Two Week Low | 2.32 |
| Financial Currency | USD |
| First Trade Date Epoch Utc | 1,784,295,000 |
| Float Shares | 86,668,206 |
| Forward Eps | -0.16 |
| Forward P E | -32.0625 |
| Free Cashflow | -15,312,625 |
| Full Time Employees | 641 |
| Fullday Price | 5.13 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.15117 |
| Gross Profits | 82,501,000 |
| Held Percent Insiders | 0.18415001 |
| Held Percent Institutions | 0.46043998 |
| Implied Shares Outstanding | 99,982,933 |
| Industry | Medical Care Facilities |
| Industry Disp | Medical Care Facilities |
| Industry Key | medical-care-facilities |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | The Oncology Institute, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support services. It also manages clinical trials and palliative care programs; operates combined community clinics and infusion suites; and operates a specialty pharmacy that includes both in-office and mail-order dispensing for complementary oral and self-injectable medications taken by patients concurrent with their in-office cancer therapies. It serves adult and senior cancer patients. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California. |
| Long Name | Starling Oncology Inc |
| Market Cap | 512,912,480 |
| Max Age | 86,400 |
| Message Board Id | finmb_661363343 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -36,324,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 646,657,749 |
| Number Of Analyst Opinions | 5 |
| Open | 4.93 |
| Operating Cashflow | -21,814,000 |
| Operating Margins | -0.04417 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 562 735 3226 |
| Previous Close | 0.0 |
| Price Hint | 2 |
| Price To Sales Trailing12 Months | 0.9398064 |
| Profit Margins | -0.079730004 |
| Quick Ratio | 1.131 |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.2 |
| Regular Market Day High | 5.15 |
| Regular Market Day Low | 4.87 |
| Regular Market Open | 4.93 |
| Regular Market Previous Close | 0.0 |
| Regular Market Volume | 1,221,151 |
| Return On Assets | -0.122980006 |
| Revenue Growth | 0.412 |
| Revenue Per Share | 5.537 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 99,982,933 |
| Shares Percent Shares Out | 0.0727 |
| Shares Short | 7,273,147 |
| Shares Short Previous Month Date | 1,781,481,600 |
| Shares Short Prior Month | 6,689,684 |
| Short Name | The Oncology Institute, Inc. |
| Short Percent Of Float | 0.083000004 |
| Short Ratio | 3.29 |
| State | CA |
| Symbol | TOI |
| Target High Price | 10.0 |
| Target Low Price | 7.0 |
| Target Mean Price | 8.4 |
| Target Median Price | 8.0 |
| Time Zone Full Name | America/New_York |
| Time Zone Short Name | EDT |
| Total Cash | 30,280,000 |
| Total Cash Per Share | 0.303 |
| Total Debt | 104,913,000 |
| Total Revenue | 545,763,968 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | NaN |
| Trailing Eps | -0.35 |
| Trailing Peg Ratio | None |
| Two Hundred Day Average | 3.87075 |
| Underlying Symbol | TOI |
| Uuid | 50f4e41b-d240-3030-8d48-ed0199bdd0cc |
| Volume | 1,221,151 |
| Website | https://theoncologyinstitute.com |
| Zip | 90,703 |